Audit complete. The soul remains.
Last Thursday, three co-founders of Project Veda posted their resignations on X. The same day, the CEO, a former tech mogul who once sold a search engine to a Chinese giant, announced the project would abandon its general-purpose Layer 1 to focus exclusively on medical data provenance. The native token crashed 40% in hours, triggering a cascade of liquidations.
I’ve been digging deep for the truth in the chain for over six years now. I’ve watched dozens of protocols pivot, shift, and sometimes vanish. But this one felt different. Veda wasn’t a DeFi microcap—it was a $200 million beast backed by top-tier VCs, with a fully functional testnet and a developer community of 5,000. Its pivot from L1 competitor to vertical healthcare infrastructure isn’t just a strategic move; it’s a confession. The general-purpose blockchain gold rush is over for all but a few. The rest must find a trench to fight in.
Context: The Rise and the Fork
Project Veda launched in early 2023, riding the wave of modular blockchain narratives. It promised a highly-scalable, EVM-compatible L1 with native AI oracles for smart contract automation. The founding team—five seasoned engineers from the crypto and AI worlds—raised $50 million at a $200 million valuation, with major contributions from a16z-style firms and Chinese internet conglomerates.
By mid-2024, however, the landscape had shifted. Solana and Base dominated user activity; new L1s like Monad and Sei were faster and more battle-tested. Veda struggled to gain traction. Its AI oracle module was still in alpha, and the team faced internal friction: half wanted to double down on L1 performance, the other half believed the real value lay in unifying blockchain with real-world healthcare data using zero-knowledge proofs. The CEO sided with the latter. The co-founders who favored the L1 path exited.
Core: The Seven Dimensions of a Desperate Gamble
Technical Architecture — From Monolith to App-Chain
Veda originally maintained its own consensus layer with a DPOS variant, requiring a global set of validators. The pivot effectively halts all L1 development. The new architecture will be a sovereign rollup on Ethereum (using Celestia as a data availability layer) specialized for healthcare data provenance. Each patient record becomes a zero-knowledge proof state transition, stored as compressed calldata.
But here’s the hidden trap: ZK proving for medical records is absurdly expensive. Based on my time auditing rollups for Synapse DAO, I can tell you that generating a proof for a 10KB medical record can cost $0.50 at current gas prices. Multiply by thousands of daily transactions—hospitals have millions of records—and the math falls apart unless gas falls to zero or the protocol subsidizes proofs via a token. Veda’s $50 million war chest can absorb that for maybe a year, but after that? The soul remains only if the economics work.
Commercialization — The Long Hard Slog of Hospital Sales
Veda’s business model now targets hospitals, pharmaceutical companies, and insurance firms. They will charge for data access, compliance audits, and perhaps a cut of drug royalty smart contracts. The CEO claims they already have LOIs with two major hospital networks in Southeast Asia.
I’ve seen this movie before. During my years building EthGallery—a DAO-governed exhibition space—I learned that enterprise sales cycles in healthcare are 18 to 24 months. Regulatory approvals (HIPAA in the US, NMPA in China, GDPR in Europe) can take years. One misstep on patient consent can shut down the entire operation. Veda’s blockchain will be only as useful as the integrations it executes. And integration requires trust, which requires time—something a burning $50 million might not provide.
Industry Impact — A Bellwether for Vertical Blockchains
Veda’s retreat from general L1 is a signal. It validates the thesis that only a handful of base layers (Ethereum, Solana, Bitcoin) will survive. Everyone else must either build an application that leverages these bases or perish. This is not a failure; it’s an evolution. The crypto industry is maturing from “everything is a blockchain” to “only the essential parts are blockchains.”
But will vertical specialization work? Consider the analogy to cloud computing: AWS didn’t win by offering a single service; it won by offering infinite specialized services. In crypto, vertical chains for finance (Maker, Compound) succeeded because they solved a specific, high-frequency problem. Healthcare data is high-value but low-frequency. Each transaction—a record update, a consent change—is rare compared to a DeFi swap. That changes the design philosophy entirely.
Competition — Staring Down Incumbents with Better Tools
The medical blockchain space is not empty. Projects like Medicalchain (patient records on Hyperledger), Solve.Care (care coordination), and even IBM’s now-defunct Healthpass have tried. Most failed because they required too much behavior change from doctors and patients. Veda’s potential edge is its large language model integration—since many of its engineers came from AI backgrounds—allowing natural language interfaces for querying records (e.g., “Show me all patients with diabetes who visited in the last month”). That could reduce friction. But it remains a feature, not a moat.
Veda’s $50 million is its strongest competitive weapon. It can hire top medical blockchain talent, run marketing campaigns, and subsidize early adoption. But that weapon has a timer. If they don’t capture a significant market share within 18 months, the capital advantage erodes.
Ethics and Safety — The Black Box of Patient Data
Healthcare blockchains must solve the impossible trinity: privacy, transparency, and verifiability. Veda proposes using zero-knowledge proofs (ZK-SNARKs) to prove that a record hasn’t been tampered with without revealing the contents. But ZK circuits have been buggy. In 2023, a critical flaw in a major ZK bridge allowed the theft of $50 million. If a similar bug affects patient data, the legal liability could bankrupt Veda overnight.
Moreover, the governance of the network becomes a life-or-death issue. If a DAO votes to change consent parameters, and a patient’s data leaks as a result, who goes to jail? The code, the founders, or the DAO itself? These are not abstract questions; they are the reason big tech regulators are circling blockchain startups. Veda’s team, which boasted blockchain engineers but not medical ethicists, now must hire an army of compliance officers. That costs money—money that could otherwise go to development.
Investment and Tokenomics — A Game of Musical Chairs
The Veda token, which originally had utility in transaction fees and staking on L1, now looks like a zombie. The pivot eliminates the need for validators; the token’s only utility will be governance and maybe a discount on data query fees. The market hated it: -40% in one day. That means the $200 million valuation is now effectively $120 million, assuming market cap matches.
VCs who invested at $200 million are now underwater. They can’t sell—lockup periods—and likely won’t participate in a down round. Veda has $50 million cash, but at their current burn rate (around $3 million per month for 200 employees), they have 16 months left. Without a new revenue source, they must reduce headcount—ironically, the medical team they just hired might be the first to go if the pivot fails to generate early contracts.
Infrastructure and Compute — From Validators to ZK Provers
The pivot dramatically changes hardware needs. Veda no longer needs a global validator network; it needs a decentralized prover network akin to Aleo or StarkNet. The CEO announced a “Prover Node” sale to raise additional capital—a risky move that could be seen as a bailout. Prover hardware is expensive (think GPU clusters), and the economics rely on token emissions to incentivize operators.
If Veda’s token price continues to fall, the incentives evaporate. Provers will leave, and the network becomes centralized on a few servers—defeating the entire purpose of a blockchain. This is a classic chicken-and-egg problem that has killed similar projects like Keep Network and NuCypher before their merger.
Contrarian: The Blind Spots the CEO Doesn’t See
Everyone is praising the pivot as “bold vision.” I think it is a Hail Mary. Here’s the contrarian angle no one mentions:
The founder’s previous attempt at medical blockchain failed. Three years ago, he started a project called “Synapse Health,” which raised $10 million but dissolved after failing to secure hospital partnerships. That experience should have taught him that healthcare is even less decentralized than finance—it’s a system of jurisdiction, not code.
Second, the timing is terrible. Interest rates are high; healthcare budgets are being cut. No hospital CIO will spend six-figure sums on experimental blockchain middleware when they can’t even afford an updated EHR system. Veda’s go-to-market strategy appears to target Southeast Asia, where regulatory oversight is lighter but purchasing power is lower.
Finally, the departure of the AI oracle co-founders wasn’t just a disagreement; they took with them the core knowledge of how to integrate language models on-chain. The remaining team might not be able to deliver the AI features that were touted as the differentiator. Veda’s execution risk just skyrocketed.
Takeaway: A Vision That Deserves to Be Wrong
I want Veda to succeed. The world needs a trust-minimized system for medical data that patients control. The economic arguments are compelling: healthcare data accounts for 30% of the world’s data volume, with massive inefficiencies in sharing and consent.
But the blockchain industry has a history of over-promising on healthcare. Patientory, HealthBlock, Medicalchain—all faded. Veda might be different because it has a war chest and a founder who is willing to make hard decisions. Yet the hardest decision—admitting that the L1 dream is dead and the new vision is a moonshot—has already been made. Now it must prove that the soul remains not just in code, but in execution.
Digging deep for the truth in the chain. I’ll be watching for three signals in the next six months: (1) a formal partnership with a top-50 hospital by bed count, (2) an open-source ZK prover that can handle 1,000 records per second under $0.01, and (3) the retention of the original engineering team that built the L1 prototype. Without those, Veda will become another case study in our industry’s arrogant failure to understand the real world.
